ArticleJournal of translational medicine2025
Screening of metabolic markers in pediatric epilepsy disorders.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Characterization of the plasma metabolomic profile in infantile epileptic spasms syndrome.Translational pediatrics · 2026Article
- The invisible emergencies: metabolic and neuro-critical disorders often missed in the pediatric ED - a narrative review.International journal of emergency medicine · 2026Review
- The associations between epilepsy, metabolism, and their clinical implications.Frontiers in endocrinology · 2026Review
- Alterations in serum metabolomics predict drug-resistant epilepsy.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe ketogenic diet (KD) has been shown to effectively reduce seizures. Ketogenic medium-chain triglycerides (MCTs) enhance brain energy metabolism in adults with neurological disorders, but their effect on peripheral metabolites in children with epilepsy is unclear. The function and mechanisms of MCTs in pediatric epilepsy remain poorly understood.
methodsWe performed untargeted LC-MS metabolomics on blood samples from children with epilepsy (n = 14) and healthy controls (n = 20), identifying octanoic acid (OA) as significantly elevated. To explore its potential role, OA was administered in a PTZ-induced seizure model in juvenile mice. Behavioral analysis, Nissl staining, and immunofluorescence demonstrated that OA modulated seizure susceptibility and activated GPR40, a receptor expressed in neurons.
results(1) A total of 518 metabolites were examined in plasma samples, with the top 20 metabolites selected, of which 14 were upregulated and 6 were downregulated. (2) In the PTZ-induced epilepsy model, OA significantly prolonged seizure latency by 59.86 ± 7.032 s (P < 0.0001), without affecting seizure grade or duration. Mechanistically, OA enhanced GPR40 activation and inhibited astrocyte activation in the hippocampus.
conclusionThis study identified and validated peripheral blood metabolites in children with epilepsy. OA was found to exert a protective effect via GPR40 activation, enhancing neuroprotection. These findings suggest that OA may play a critical role in neuroprotection and could serve as a potential therapeutic target for pediatric epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.